Transapical aortic valve replacement through a chronic apical aneurysm
Related Experiment Video
Updated: May 26, 2026

Novel and Innovative Hybrid Technique for Type A Aortic Dissection
Published on: March 28, 2025
Enrico Ferrari1, Fabrizio Gronchi, Salah Dine Qanadli
1Department of Cardiovascular Surgery, CHUV, University Hospital of Lausanne, Lausanne, Switzerland. enricoferrari@bluewin.ch
Abstract:
Transapical aortic valve replacement through an apical aneurysm is traditionally contraindicated because of the risk of severe systemic embolization when thrombi are present. However, a chronic fibrotic aneurysm without apical thrombi carries a low risk of distal embolization and can be safely employed for a transapical transcatheter aortic valve replacement in case of absence of an alternative access site (severe vascular disease, small vascular sizes and diseased calcified aorta). We illustrate our experience with a 73-year-old patient suffering from symptomatic aortic valve stenosis, coronary artery disease with occluded left anterior descending artery, left ventricular apical aneurysm and severe peripheral vascular disease, who successfully underwent a transapical 26 mm Sapien™ XT stent-valve implantation through the fibrotic thin akinetic apical wall.
Related Concept Videos
Aneurysm III: Interprofessional Care
Aortic Regurgitation III: Medical Management
Aortic Regurgitation I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aneurysm I: Introduction

